Chaque année au Royaume-Uni, 2 400 deaths are caused by cancers linked to the uterus and 9,700 new cases are detected according to Cancer Research. In France, every year, nearly 3,000 women suffer from this disease, and 1,000 of them die. The most common forms of the disease are endometrial cancer and uterine sarcoma.
Dostarlimab – A Breath of Hope
Also known as Jemperli, Dostarlimab is a medicine that could improve the quality of life of patients with uterine cancer. This immunotherapy works by attracting certain proteins to the surface of cancer cells to help the immune system attack them. These are laboratory-produced antibodies, which are administered by drip for half an hour under the supervision of a doctor.
According to tests, this medication will also extend the patient’s life expectancy when used in combination with chemotherapy.
Encouraging Clinical Trials
In fact, clinical trials have shown that 64% of patients who received the Dostarlimab treatment, besides their chemotherapy, did not have their cancer worsen after a year of treatment. This figure is twice as high as chemotherapy alone. The good news is that the medication was approved by the Medicines and Healthcare Products Regulatory Agency last October. It is the first medication approved as a first-line treatment for advanced or recurrent primary endometrial cancer. up to 200 people can benefit from benefits each year.
“The launch of this medication as a first-line treatment on the NHS is good news for patients suffering from this type of uterine cancer – this new immunotherapy could offer hundreds of women the hope of a precious future where they can live well before their cancer progresses,” said Professor Peter Clark, head of the cancer drug fund.
Source: The Guardian